The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century,
coincident with marketing of aspirin—a signature event in the history of modern drug …

Targeting RNAs with small molecules represents a new frontier in drug discovery and
development. The rich structural diversity of folded RNAs offers a nearly unlimited reservoir …

COVID-19 is a global pandemic, thus requiring multiple strategies to develop modalities
against it. Herein, we designed multiple bioactive small molecules that target a functional …

Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This
typically relies on a measurable biochemical readout and accessible binding sites whose …

RNA offers nearly unlimited potential as a target for small molecule chemical probes and
lead medicines. Many RNAs fold into structures that can be selectively targeted with small …

Abstract Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are
important for tumorigenesis has emerged as a potential therapeutic strategy for cancer …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that
utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI) …

RNAs have important functions that are dictated by their structure. Indeed, small molecules
that interact with RNA structures can perturb function, serving as chemical probes and lead …

Many RNAs are processed into biologically active transcripts, the aberrant expression of
which can contribute to disease phenotypes. For example, the primary microRNA-17-92 (pri …

The design and discovery of small molecule medicines has largely been focused on a small
number of druggable protein families. A new paradigm is emerging, however, in which small …